|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The median methylation level of MGMT in glioma samples was 64.65% (IQR, 54.87%-74.37%) compared to 38.30% (IQR, 34.13%-45.45%) in healthy controls, and all revealed significant differences including P16.
|
29100349 |
2017 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma.
|
28693158 |
2017 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We studied tumor purity, pTERT mutation by Sanger sequencing, MGMT methylation by pyrosequencing, IDH1 mutation status, and clinical parameters in a cohort of high-grade gliomas (<i>n</i> = 97).
|
28148826 |
2017 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
However, the promoter regions the methylation of which correlates best with survival in aggressive glioma and whether the promoter methylation status predictive value could be refined or improved by other MGMT-associated molecular markers are not precisely known.
|
26717998 |
2016 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The association between gene copy number variation, predicted MGMT methylation, and MGMT expression revealed a gene dosage effect on MGMT expression in lower grade glioma (World Health Organization grade II/III) that in contrast to glioblastoma usually carry two copies of chromosome 10 on which MGMT resides (10q26.3).
|
26927331 |
2016 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation is a marker for poor prognosis in human glioma, while, MGMT methylation is a sensitive marker of glioma cells to alkylating agents.
|
26967246 |
2016 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) causes resistance of cancer cells to alkylating agents and, therefore, is a well-established predictive marker for high-grade gliomas that are routinely treated with alkylating drugs.
|
27158275 |
2016 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In whole 87 CpG dinucleotides analyzed, three distinct CpG regions covering 28 CpG dinucleotides were significantly correlated with MGMT gene expression; 10 CpG dinucleotides were significantly correlated with glioma classification (p < 0.05).
|
27468718 |
2016 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Completeness of MGMT and 1p/19q codeletion was highest for glioma subtypes for which testing is recommended by clinical practice guidelines.
|
27418206 |
2016 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
|
25682093 |
2015 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The dealkylating effect of MGMT is relevant not only in repairing DNA mismatches produced by environmental alkylating agents promoting tumor pathogenesis, but also when alkylating molecules are applied in the chemotherapy of different cancers, including glioma, the most common primary tumor of the central nervous system.
|
26035292 |
2015 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation represents a favorable prognostic factor and has been associated with a better response to alkylating agents in glioma and systemic lymphoma.
|
25031012 |
2014 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors.
|
24325789 |
2014 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT (O(6)-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic silencing is used for predicting the response to the alkylating drug temozolomide in patients with glioma.
|
24709436 |
2014 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associated with IDH1/2 mutation, 1p/19q codeletion, and MGMT promoter methylation using a single assay.
|
25028501 |
2014 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study provides evidence that DNA repair genes ERCC1, ERCC2, and XRCC1 might be low-penetrance glioma-risk genes, while MGMT and PARP1 polymorphisms may confer protection against glioma.
|
24500421 |
2014 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
(11)C-methionine PET could be a useful tool to detect MGMT promoter methylation in nonenhancing glioma.
|
25178915 |
2014 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study aimed to: (i) evaluate the concordance between MGMT promoter methylation status in tumor tissue and plasma; (ii) monitor MGMT promoter methylation status in plasma taken before and during temozolomide treatment; (iii) explore the value of MGMT promoter methylation status in plasma as a prognostic/predictive biomarker in glioma patients.
|
24519517 |
2014 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioma cells rich in miR-181b were more sensitive to temozolomide. miR-181b expression was not correlated with MGMT promoter methylation status. miR-181b combined with temozolomide enhanced glioma cell sensitivity and apoptosis.
|
23645289 |
2013 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Detection of IDH1 mutations and the status of MGMT promoter on intraoperative fresh tissue section from frameless neuronavigation needle biopsy. Analysis on 17 patients with brain glial tumor ineligible for craniotomy and tumor resection.
|
21781445 |
2013 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
|
24068788 |
2013 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the "triple negative" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance.
|
23288644 |
2013 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Finally, we determined that the sensitivity of each primary GBM cells and glioma cell lines to the lomeguatrib-TMZ combination was different and significantly associated with the structure of MGMT methylation.
|
23519841 |
2013 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
This review summarizes the existing data that support the rationale for MGMT promoter methylation testing and possibly other molecular testing in clinically defined glioma subtypes.
|
23871769 |
2013 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the effect of typical polymorphisms of MTHFR (C677T and A1298C) on MGMT methylation based on different serum folate levels in patients with glioma from Northeast China.
|
24301776 |
2013 |